Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 | P33527 | 19/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14486417 | 0.91 | HTR1A (0.42) | HTR1AHTR7 | |
| SCHEMBL15664366 | 0.91 | HTR1A (0.42) | ABCC1CYP3A4HTR1A | |
| SCHEMBL14486750 | 0.90 | SMYD2 (0.42) | CYP3A4HTR1AHTR7 | |
| SCHEMBL14555554 | 0.87 | MAPT (0.40) | HTR1AHTR7 | |
| SCHEMBL14486076 | 0.87 | SIGMAR1 (0.49) | HTR1A | |
| SCHEMBL14486516 | 0.86 | ABCC1 (0.43) | ABCC1CYP3A4HTR1AHTR7 | |
| SCHEMBL15700543 | 0.85 | NPC1 (0.36) | ABCC1CYP3A4 | |
| SCHEMBL14486376 | 0.85 | SIGMAR1 (0.47) | — | |
| SCHEMBL14488466 | 0.84 | HTR1A (0.46) | CYP3A4HTR1A | |
| SCHEMBL14486203 | 0.84 | FAAH (0.39) | ABCC1CYP3A4HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023852-B2 | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2015-05-05 | — | — | US | claimed |
| EP-2726470-B1 | 1,2,4-THIADIAZOL-5-YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2015-04-29 | — | — | EP | claimed |
| CN-103619825-A | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment neurodegenerative diseases | REMYND NV | 2014-03-05 | — | — | CN | claimed |
| US-9023852-B2 | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2015-05-05 | — | — | US | disclosed |
| EP-2726470-B1 | 1,2,4-THIADIAZOL-5-YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2014-05-08 | — | — | US | disclosed |
| EP-2726470-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | reMynd NV (BE) | 2014-05-07 | — | — | EP | disclosed |
| CN-103619825-A | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment neurodegenerative diseases | REMYND NV | 2014-03-05 | — | — | CN | disclosed |
| WO-2013004642-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | MAPT, PSEN1, PSEN2 | ABCC1 1305/4885CYP3A4 3554/4885HTR1A 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.